Abstract
A series of quinoxaline analogs of the herbicide Assure® was found to have selective cytotoxicity for solid tumors of mice in a disk-diffusion-soft-agar-colony-formation-assay compared to L1210 leukemia. Four agents without selective cytotoxicity and 14 agents with selective cytotoxicity were evaluated in vivo for activity against a solid tumor. The four agents without selective cytotoxicity in the disk-assay were inactive in vivo (T/C > 42%). Thirteen of the fourteen agents with selectivity in the disk-assay were active in vivo (T/C < 42%). Five of the agents had curative activity. These five agents had a halogen (F, Cl, Br) in the 7-position (whereas Assure® had a Cl in the 6 position). All agents with curative activity were either a carboxylic acid, or a derivative thereof, whereas Assure® is the ethyl ester of the carboxylic acid. All other structural features were identical between Assure® and the curative agents. Assure® had no selective cytotoxicity for solid tumors in the disk-assay, and was devoid of antitumor activity. The analog XK469 is in clinical development.
Similar content being viewed by others
References
Branda RF, McCormack JJ, Perlmutter CA: Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound inmurine B16 melanoma cells. Biochem Pharmacol 37: 4557–4564, 1988
Branda RF, Moore AL, McCormack JJ: Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol 38: 3521–3526, 1989
Rigas JR, Francis PA, Miller VA et al.: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 35(6): 483– 488, 1995
Conley BA, O'Hara S, Wu S et al.: Phase I trial of chloroquinoxaline sulfonamide with correlation of its pharmacoki netics and pharmacodynamics. Cancer Chemother Pharmacol 37: 139–149, 1995
Miller VA, Rigas JR, Tong WP et al.: Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 40(4): 415–418, 1997
Craciunescu et al.: An R Acad Farm 51: 653–658, 1985
Foster et al.: Invest New Drugs 3: 401–410, 1985
Katagiri K, Yoshida T, Sato K: Quinoxaline antibiotics. In: Antibiotics, Vol III, Mechanism of Action of Antimicrobial and Antitumor Agents. Corcorn and Hahn (eds), Springer-Verlag, pp 234–251, 1974
Piatti SE, Bekerman D, Gaozza CH: Es </del>Sintesis de Derivados de bis-quinoxalina con posible actividad antineoplasica. Anales de Quimica, Ser. C 82: 85–89, 1986
Piatti SE, Nuber N, Krotz L, Gaozza CH: Sintesis de Derivados de Bisaminoquinoxalina. Ensayos de Interaccion con adn y de citotoxicidad. Anales de Quimica 85: 105–109, 1989
Zegar I, Graslund A, Bergman J, Eriksson M, Norden B: Interaction of ellipticine and a Indolo [2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides. Chem Biol Interactions 72: 277–293, 1989
Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical antitumor activity of XK469. EORTC 104,1994
LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical Antitumor Activity of XK469. Proc. of AACR 35: 401, 1994
Corbett T, Valeriote F, LoRusso P et al.: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Intern J Pharmacognosy (Supp) 33: 102–122, 1995
Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42: 1707–1715, 1982
Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold Jr DP, Schabel Jr FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187– 1200, 1982
Corbett T, Valeriote F, Baker L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5: 3–20, 1987
Corbett TH, Valeriote FA: Rodent Models in Experimental Chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, R.F. Kallman (ed) Pergamon Press, Chapt. 50, pp 233–247, 1987
Corbett TH, Valeriote FA, Polin L et al.: Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay. In: Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. FA Valeriote, TH Corbett, LH Baker (eds), Kluwer Academic Publishers, pp 33–87, Boston/Dordrecht/London, 1992
Corbett T, Valeriote F, LoRusso P et al.: In Vivo Methods for Screening and Preclinical Testing; Use of rodent solid tumors for drug discovery. In: The Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. B Teicher (ed), Humana Press Inc., Totowa, NJ Chapt-5, pp 75–99, 1997
Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434–2439, 1975
Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660–2680, 1977
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57Bl/6 mice. Cancer Res 44: 717–726, 1984
Corbett TH: A selective two-tumor soft agar assay for drug discovery. AACR, Abst. No. 1289, 25: 325, 1984
Corbett T, Valeriote F, Baker L et al.: Antitumor activity of N-[[1–[[2–(Diethylamino)ethyl]amino]-9–oxo-9H-Thioxanthen-4–y1]methyl]metanesulfonamide (WIN33377) and analogs: Expert Opinion on Investigational Drugs 3(12): 1281–1292, 1994
Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of cryptophycin-8. J Exper Therap Oncol 1: 95–108, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corbett, T.H., LoRusso, P., Demchick, L. et al. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 16, 129–139 (1998). https://doi.org/10.1023/A:1006174622061
Issue Date:
DOI: https://doi.org/10.1023/A:1006174622061